[HTML][HTML] Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients
JA Khoury, GA Storch, DL Bohl, RM Schuessler… - American Journal of …, 2006 - Elsevier
Prophylaxis reduces cytomegalovirus (CMV) disease, but is associated with increased costs
and risks for side effects, viral resistance and late onset CMV disease. Preemptive therapy …
and risks for side effects, viral resistance and late onset CMV disease. Preemptive therapy …
[HTML][HTML] Valacyclovir prophylaxis versus preemptive valganciclovir therapy to prevent cytomegalovirus disease after renal transplantation
T Reischig, P Jindra, O Hes, M Švecová… - American Journal of …, 2008 - Elsevier
Both preemptive therapy and universal prophylaxis are used to prevent cytomegalovirus
(CMV) disease after transplantation. Randomized trials comparing both strategies are …
(CMV) disease after transplantation. Randomized trials comparing both strategies are …
Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: 1-year results of a randomized clinical trial
O Witzke, IA Hauser, M Bartels, G Wolf, H Wolters… - …, 2012 - journals.lww.com
Background. Cytomegalovirus (CMV) prevention can be achieved by prophylaxis or
preemptive therapy. We performed a prospective randomized trial to determine whether …
preemptive therapy. We performed a prospective randomized trial to determine whether …
[HTML][HTML] The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high‐risk kidney transplant recipients
A Humar, Y Lebranchu, F Vincenti, EA Blumberg… - American Journal of …, 2010 - Elsevier
Late‐onset cytomegalovirus (CMV) disease is a significant problem with a standard 3‐month
prophylaxis regimen. This multicentre, double‐blind, randomized controlled trial compared …
prophylaxis regimen. This multicentre, double‐blind, randomized controlled trial compared …
Extended valganciclovir prophylaxis in D+/R− kidney transplant recipients is associated with long-term reduction in cytomegalovirus disease: two-year results of the …
A Humar, AP Limaye, EA Blumberg, IA Hauser… - …, 2010 - journals.lww.com
Background. Whether the early reduction in cytomegalovirus (CMV) disease seen at 1 year
with prolongation of antiviral prophylaxis (up to 200 days) persists in the long term is …
with prolongation of antiviral prophylaxis (up to 200 days) persists in the long term is …
Long-term outcomes of pre-emptive valganciclovir compared with valacyclovir prophylaxis for prevention of cytomegalovirus in renal transplantation
T Reischig, P Hribova, P Jindra, O Hes… - Journal of the …, 2012 - journals.lww.com
Prevention of cytomegalovirus (CMV) is essential in organ transplantation. The two main
strategies are pre-emptive therapy, in which one screens for and treats asymptomatic CMV …
strategies are pre-emptive therapy, in which one screens for and treats asymptomatic CMV …
Prophylactic Oral Ganciclovir Compared With Deferred Therapy For Control Of Cytomegalovirus In Renal Transplant Recipients1, 2
DC Brennan, KA Garlock, GG Singer… - …, 1997 - journals.lww.com
Background. Treatment with prophylactic oral acyclovir, intravenous ganciclovir, or
immunoglobulins to prevent cytomegalovirus (CMV) infection and disease in renal …
immunoglobulins to prevent cytomegalovirus (CMV) infection and disease in renal …
Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: long-term results after 7 years of a randomized clinical trial
O Witzke, M Nitschke, M Bartels, H Wolters… - …, 2018 - journals.lww.com
Background The VIPP study compared valganciclovir prophylaxis with preemptive treatment
regarding efficacy, safety, and long-term graft outcome in cytomegalovirus (CMV)-positive …
regarding efficacy, safety, and long-term graft outcome in cytomegalovirus (CMV)-positive …
Increased risk of breakthrough infection among cytomegalovirus donor‐positive/recipient‐negative kidney transplant recipients receiving lower‐dose valganciclovir …
DR Stevens, D Sawinski, E Blumberg… - Transplant Infectious …, 2015 - Wiley Online Library
Objective We compared the effectiveness of lower‐dose (LD)(450 mg/day for 6 months) to
standard‐dose (SD)(900 mg/day for 6 months) valganciclovir (VGCV) prophylaxis for …
standard‐dose (SD)(900 mg/day for 6 months) valganciclovir (VGCV) prophylaxis for …
[HTML][HTML] Primary CMV infections are common in kidney transplant recipients after 6 months valganciclovir prophylaxis
I Helanterä, L Kyllönen, I Lautenschlager… - American Journal of …, 2010 - Elsevier
Prolonging cytomegalovirus (CMV) prophylaxis in CMV seronegative recipients of a kidney
from CMV seropositive donor (D+/R–) may reduce the incidence of late infections. We …
from CMV seropositive donor (D+/R–) may reduce the incidence of late infections. We …
相关搜索
- preemptive therapy valganciclovir prophylaxis
- allograft recipients valganciclovir prophylaxis
- allograft recipients preemptive therapy
- transplant recipients cytomegalovirus infection
- cmv infections valganciclovir prophylaxis
- kidney recipients ganciclovir prophylaxis
- cytomegalovirus disease ganciclovir prophylaxis
- cytomegalovirus disease kidney recipients
- cytomegalovirus disease valganciclovir therapy
- renal transplantation valganciclovir therapy
- cytomegalovirus disease renal transplantation
- cytomegalovirus disease valganciclovir prophylaxis
- breakthrough infection valganciclovir prophylaxis
- control of cytomegalovirus transplant recipients1
- renal transplantation prevention of cytomegalovirus